Search results

Lege Artis Medicinae

DECEMBER 10, 2019

[The adverse effects of smoking on our respiratory system based on data of the Hungarian Public Health Screening 2010-2018 ]

KÉKES Ede, DAIKI Tenno, DANKOVICS Gergely, BARNA István

[The regular smoking with or without clinical symptoms causes structural changes in the lung tissue and this is reflected in res­pi­ratory function tests. During the last 9 years of Hungary's comprehesive health promotion screening (MÁESZ) between 2010 and 2018, spiro­metric examinations (PEF, FEV1, MEF25-75, FVC) were performed on 70822 women and 60187 men. We used the percentage of predictive values in the analysis to describe the deviation from normal. The carbon monoxide (eCO) content measurement of the exhaled air (in ppm) was performed on 24899 women and 22340 men. The COPD Evaluation Ques­tionnaire (CAT) was completed by 4166 wo­men and 3170 men. All four parameters of spirometry showed lower values for smokers in both sexes, but in men they were lower than in women. Ageing lowered significantly the values. The rate of changes from normal predictive values and the difference between smokers and non-smokers was the highest for MEF25-75 and FVC. The expiratory CO content (eCO) was significantly higher in smokers than in non-smokers in all age groups. In smokers, the incidence in percent of abnormal CAT score was significantly higher. Respiratory screening tests reveal the harmful effects of smoking, even without clinical symptoms, and indicate the risk of developing COPD.]

Hypertension and nephrology

DECEMBER 20, 2016

[Deeper analysis of nebivolol effects]

KÉKES Ede

[Author presents the formation of nitric oxide as a largest vasodilator of human endothelium as well as the endothelial dysfunction a result of formation at adrenergic stimulus. He demonstrates in detail the benefits of selective β-1 blocker and β-3 adrenergic agonist nebivolol in the vascular system. This drug has also receptor independent effects. Complex effects of nebivolol causes vasodilation, inhibits oxidative stress and it is capable to neutralize the effects of free oxygen radicals and as a result the endothelial function will be better. Its clinical effects and the less wellknown beneficial properties are listed. The use of drug is discussed especially in hypertensives with smoking, COPD or PAD. The β-3 agonist effect provides positive reactions not only in the adipocytes and the myocardial tissue. but in the skeletal muscle as well: Increase in energy expenditure - as a compensatory mechanism - is increased in obesity and the glucose uptake + storage on skeletal muscle cells are increased in hyperglycemia. The insulin sensitivity will be better, leptin level is decreased, adiponectin level is increased by nebivolol. It is assumed this drug has antidiabetic and anti-obesity effects.]

Lege Artis Medicinae

DECEMBER 15, 2015

[The asthma-COPD overlap syndrome]

NAGY László Béla

[The asthma bronchiale and chronic obstructive pulmonary disease (COPD) are not simple diseases, but heterogenous syndromes. In their most typical forms, asthma and COPD are clearly distinguishable, but many patients demonstrate features of both conditions. This is the asthma - COPD overlap syndrome (ACOS). We present the latest findings in the pathogenesis, clinical characterisation, diagnosis, and management of ACOS. Because the limitations of the studies need future research, mainly to develop targeted therapy. ]

Lege Artis Medicinae

JUNE 01, 2015

[Role of roflumilast in chronic obstructive lung disease]

NAGY László Béla

[The phosphodiesterase 4 inhibitor roflumilast supresses the function of a range of inflammatory cells and mediators contributing in the pathogenesis of chronic obstructive lung disease (COPD). This article reviews the current status of roflumilast, focusing on the pharmacokinetics, efficacy and safety. Phase III clinical trials have demonstrated that roflumilast reduces exacerbation frequency with accompanying improvements in lung function. This effect appeared to be the greatest in the phenotypes of patients who have frequent acute exacerbations, or/and whose characteristic feature is chronic bronchitis. It can presumably also reduce systemic inflammation. Such effect has not been documented in COPD yet. It is generally well tolerated, but the most common adverse effects include diarrhea, nausea, and headaches. Roflumilast is a promising drug as a supplementary therapy when symptoms are not adequately controlled by conventional COPD therapy.]

LAM Extra for General Practicioners

DECEMBER 15, 2011

[ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH COPD - THE SIGNIFICANCE OF NEBIVOLOL]

FARSANG Csaba

[The occurrence of hypertension associated with chronic obstructive pulmonary disease (COPD) is increasing. Recognising COPD is important in order to choose the appropriate antihypertensive drugs. Antihypertensive drugs that can be used to treat patients with hypertension and COPD include diuretics, ACE-inhibitors, angiotensine receptor blockers (AT1 receptor antagonists) and calcium antagonists, as well as cardioselective beta blockers, as these drugs decrease total and cardiovascular mortality. Of these agents, the importance of the most cardioselective one, nebivolol should be stressed, as this drug has no clinically significant effect on parameters of respiratory function, and, through its additional effects (namely by increasing the synthesis of NO), it has a beneficial effect on COPD-related deterioration of respiratory functions, haemodynamic alterations (cor pulmonale) and local factors that participate in the respiratory inflammation and endothelial dysfunction.]

Hypertension and nephrology

DECEMBER 20, 2011

[Antihypertensive therapy in patients with COPD - the significance of nebivolol]

FARSANG Csaba

[The occurrence of hypertension associated with chronic obstructive pulmonary disease (COPD) is increasing. Recognising COPD is important in order to choose the appropriate antihypertensive drugs. Anti-hypertensive drugs that can be used to treat patients with hypertension and COPD include diuretics, ACE-inhibitors, angioten-sine receptor blockers (AT1 receptor antagonists) and calcium antagonists, as well as cardioselective beta blockers, as these drugs decrease total and cardiovascular mortality. Of these agents, the importance of the most cardioselective one, nebivolol should be stressed, as this drug has no clinically significant effect on parameters of respiratory function, and, through its additional effects (namely by increasing the synthesis of NO), it has a beneficial effect on COPD-related deterioration of respiratory functions, haemodynamic alterations (cor pulmonale) and local factors that participate in the respiratory inflammation and endothelial dysfunction.]

Lege Artis Medicinae

NOVEMBER 20, 2011

[Antihypertensive therapy in patients with COPD 699 - The significance of nebivolol]

FARSANG Csaba

[The occurrence of hypertension associated with chronic obstructive pulmonary disease (COPD) is increasing. Recognising COPD is important in order to choose the appropriate antihypertensive drugs. Antihypertensive drugs that can be used to treat patients with hypertension and COPD include diuretics, ACE-inhibitors, angiotensine receptor blockers (AT1 receptor antagonists) and calcium antagonists, as well as cardioselective beta blockers, as these drugs decrease total and cardiovascular mortality. Of these agents, the importance of the most cardioselective one, nebivolol should be stressed, as this drug has no clinically significant effect on parameters of respiratory function, and, through its additional effects (namely by increasing the synthesis of NO), it has a beneficial effect on COPD-related deterioration of respiratory functions, haemodynamic alterations (cor pulmonale) and local factors that participate in the respiratory inflammation and endothelial dysfunction.]

Lege Artis Medicinae

FEBRUARY 20, 2005

[LONG-TERM OXYGEN TREATMENT]

SOMFAY Attila

[Long-term oxygen therapy is the only treatment that has been shown to significantly improve life expectancy in patients with severe chronic obstructive pulmonary disease (COPD) exhibiting marked hypoxemia. There has been sginificant advances in the longterm oxygen therapy in the last two decades caused by the technological improvements in oxygen delivery systems as well as our better knowledge of the beneficial effects of the longterm oxygen therapy including better quality of life, exercise tolerance and pulmonary hemodynamic effects. This expansive therapy requires the documentation of chronic arterial hypoxemia by arterial blood gas analysis or pulsoximetry which should be reassesed during chronic care of these patients. Besides hypoxaemia, the consequences of tissue hypoxia induced by different problems in the oxygenation chain should also be considered. Indication of long-term oxygen therapy is optimally based on evidence and pathophysiology, thereby the undesirable placebo effect or psychological addiction to oxygen can be reduced. Late laboratory diagnostics and poor patient compliance are the main determinants of undertreatment. The real value of the long-term oxygen therapy in indications other than hypoxaemic COPD requires more controlled studies.]